RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine

Cetuximab and panitumumab monoclonal antibodies are a milestone in the history of treatment of metastatic colorectal cancer (mCRC) and point toward future directions for personalized treatment. Recent studies have shown that broader RAS testing is needed to select patients for targeted therapy. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentini, Anna M., Cavalcanti, Elisabetta, Di Maggio, Marianna, Caruso, Maria L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135466/
https://www.ncbi.nlm.nih.gov/pubmed/30199395
http://dx.doi.org/10.1097/PAI.0000000000000475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135466/
https://www.ncbi.nlm.nih.gov/pubmed/30199395
http://dx.doi.org/10.1097/PAI.0000000000000475

Ejemplares similares